Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Long before I saw you here, she had already died many times.
Those who are believed to be dead live longer.
Thanks. The volume is amazing, a 100%day would not surprise me.
GLTA
Thanks CC. When do you think they will let the cat out of the bag and announce the exact future business area of the company (this unborn would also need a new name).
Does anyone see a connection with the Ukraine crisis or is it pure coincidence that the share price is exploding right now?
??- What's going on here? I've been in for a few years and have looked in now and then. Thanks Winning and everyone else for the DD. What do you guys think is a realistic short term price target?
Selflessly disinterested philanthropists can, of course, judge others from afar.
How protein-based COVID vaccines could change the pandemic
iBio Acquires FastPharming Manufacturing Facility®
November 03, 2021 16:47 ET | Source: iBio, Inc.
- Takes Sole Ownership of CDMO Subsidiary & U.S. Manufacturing Rights -
- Reduces Carrying Costs by Approximately 67% -
BRYAN, Texas, Nov. 03, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming System, today announced it has purchased the manufacturing facility it previously operated under a lease from two affiliates of Eastern Capital Limited (the “Eastern Affiliates”). The Company also acquired the approximate 30% equity interest in iBio CDMO, LLC. (the “CDMO”) held by the Eastern Affiliates. As a result, the subsidiary and its intellectual property are now wholly-owned by iBio.
https://www.globenewswire.com/news-release/2021/11/03/2326945/0/en/iBio-Acquires-FastPharming-Manufacturing-Facility.html
It's a shitty situation that we have to live through on this barge and I don't blame anyone who gets off the boat disappointed and angry. We bought shares of this company by our own free choice and everyone is free to sell them whenever he or she wants to.
I will stay on board as long as I can imagine the situation to exit prematurely worse than the reality at the moment. Also, I see a future market for what this company is doing - I am very curious to see how the market will react once Medicago successfully completes Phase3. Even if there is no direct connection to us, their success will draw more eyes from investors also to this company.
Good luck to you!
Oh yes ... And one thing is also clear, the story could have ended differently.
Decide, no matter whether you still go down or possibly discover America. But stop showing off your disappointed greed or celebrating your opportunism, your gloating, your sarcasm. Live or go down with balls in your pants!
Disembarks, mutinies or tries to navigate back even though the point of no return has already been passed. Of course, you can also trust the captain ... all lamenting is futile in the end - a decision is inevitable either way. The present situation reminds me of the story of the discovery of America: "More than a month had passed since the departure from the Canary Islands, and none of those present had ever made a long sea voyage with no land in sight. Columbus cheered up the crews and tried to convince the sailors of the advantages that awaited them on land. Besides, he said, complaints were useless because it was now decided to get to India to find a shorter trade route. Columbus summoned his authoritative companions to get out one last deadline of three days, which he succeeded in doing ..." The rest of the story is known ... a new continent was discovered.
The same joke as 6 days ago. A joke works on the punch line, if it is known ... the rest I leave to your acumen.
Open Access to the $iBio FastPharming® Platform
Factory Solutions is rooted in iBio’s guiding philosophy of empowering companies to fully capitalize on the advantages of FastPharming – iBio’s proprietary approach to plant-made pharmaceutical (PMP) production. Supporting our product and equipment solutions is a team comprised of PMP experts who fully understand the science behind our technology and are experts in the full complement of PMP processes, equipment, technologies, and facility design - including the demands of operating a hydroponic facility within a cGMP environment.
iBio’s Factory Solutions puts our PMP experts and architectural and engineering partners to work, enabling companies to leverage all the benefits of the FastPharming System. The Factory Solutions program offers:
Process design, optimization, and scale-up
Product feasibility studies
Training
Technology transfer
Research, pilot or commercial-scale facility design
Regulatory review and support
By being hands-on with products and processes within our Bryan, TX facility, our development team can quickly adapt to what is learned during the feasibility and process development stages. As a result, not only can your specific product, process, and facility design be perfected, you can begin your path to the clinic while your PMP production capabilities are coming online.
iBio's facility was built greenfield to completion within thirteen months.
#iBio - $ibio - ibio
butterflies
" ... A third company that is making headway is Texas-based iBio, which is working on several vaccine candidates. These include a virus-like particle, a subunit vaccine, and a second-generation vaccine that targets the SARS-CoV-2 virus's N protein, which is more conserved than the spike protein ... "
https://bigthink.com/surprising-science/plant-based-vaccines-can-change-the-vaccine-landscape
You have not read the article carefully - in the last third is written about iBio!
Plant-based vaccines can change the vaccine landscape - Big Think
https://bigthink.com/surprising-science/plant-based-vaccines-can-change-the-vaccine-landscape
$iBio - iBio - #iBio
the start up of the dictatorship of capital
Corporate Presentation iBio Inc. March 21
Rapid Increase in End-use Adoption to Boost Plant-based Biologics Market Revenue Growth
ResearchDive - May 3, 2021
https://ksusentinel.com/2021/05/03/rapid-increase-in-end-use-adoption-to-boost-plant-based-biologics-market-revenue-growth/
So it‘s better to sell or what’s your assessment of the stock if you think the CEO is a „douche“?
https://thoughtcatalog.com/lorenzo-jensen-iii/2016/06/31-hilarious-ways-to-explain-exactly-what-a-douchebag-really-is/
Customized Glycoengineering in Plant-Based Expression Systems
iBio describes its FastPharming® system, which uses plants as bioreactors, simplifies glycoengineering, and expedites process development
https://www.genengnews.com/resources/tutorial/customized-glycoengineering-in-plant-based-expression-systems/
A remarkably emotional reaction for a professional. Leave the "to talk down" to someone earning money with that. Unless ...
Protein-Based Vaccines
Vaccines that contain coronavirus proteins but no genetic material. Some vaccines contain whole proteins, and some contain fragments of them. Some pack many of these molecules on nanoparticles.
PHASE 3
Novavax logo
Maryland-based Novavax makes vaccines by sticking proteins onto microscopic particles. They’ve taken on a number of different diseases this way; their flu vaccine finished Phase 3 clinical trials in March. The company launched trials for a Covid-19 vaccine in May, and the Coalition for Epidemic Preparedness Innovations has invested $384 million in the vaccine. In July the U.S. government awarded Novavax another $1.6 billion to support the vaccine’s clinical trials and manufacturing.
After getting promising results from preliminary studies in monkeys and humans, Novavax launched a Phase 2 trial in South Africa in August. The blinded, placebo-controlled trial on 2,900 people will measure not just the safety of the vaccine but its efficacy. The following month, Novavax launched a Phase 3 trial enrolling up to 15,000 volunteers in the United Kingdom. It is expected to deliver results in early 2021. A larger Phase 3 trial in the United States is expected to launch by the end of December.
In September Novavax reached an agreement with the Serum Institute of India, a major vaccine manufacturer, that they said would enable them to produce as many as 2 billion doses a year. If the trials succeed, Novavax expects to deliver 100 million doses for use in the United States by the first quarter of 2021. On Nov. 4 they announced another agreement to deliver 40 million doses to Australia.
Updated Nov. 30
PHASE 2 PHASE 3 COMBINED PHASES
Medicago logoGSK logo
Canada-based Medicago, partly funded by the cigarette maker Philip Morris, grow vaccines in a plant called Nicotiana benthamiana, a wild species related to tobacco. They deliver virus genes into leaves, and the plant cells then create protein shells that mimic viruses. In July, Medicago launched Phase 1 trials on a plant-based Covid-19 vaccine in combination with adjuvants to boost the immune system’s response to the viral proteins. In that study, they found that an adjuvant made by GSK produced promising levels of antibodies in volunteers. On Oct. 23, the company announced it had reached an agreement with the government of Canada to supply 76 million doses. A Phase 2/3 trial of the vaccine began on Nov. 12.
Updated Nov. 24
PHASE 3
Anhui Zhifei Longcom logoInstitute of Medical Biology at the Chinese Academy of Medical Sciences logo
The Chinese company Anhui Zhifei Longcom and the Chinese Academy of Medical Sciences partnered to make a vaccine. Their candidate is composed of an adjuvant, along with a section of the spike protein called the receptor-binding domain. They launched Phase 2 trials in July, followed by a Phase 3 trial with 29,000 volunteers in December.
Updated Dec. 2
PHASE 1 PHASE 2 COMBINED PHASES
Finlay Vaccine Institute logo
On Aug. 18, the head of epidemiology at Cuba’s public health ministry announced that the Finlay Vaccine Institute in Havana would start a clinical trial on a vaccine for Covid-19. The vaccine, called Soberana 1, contains a part of the spike protein, called RBD, along with two extra ingredients: proteins from a bacteria and aluminum hydroxide. These ingredients, known as adjuvants, boost the immune system’s response to the coronavirus RBD.
Updated Oct. 28
PHASE 1 PHASE 2 COMBINED PHASES APPROVED FOR EARLY USE IN RUSSIA
Vector Institute logo
On Aug. 26, the Vector Institute, a Russian biological research center, registered a Phase 1/2 trial for a coronavirus vaccine they call EpiVacCorona. The vaccine contains small portions of viral proteins, known as peptides. According to newspaper reports, the EpiVacCorona trials had already begun by then. On October 14, Vladimir Putin announced that Russia has granted regulatory approval to EpiVacCorona, making it the second vaccine to receive that designation after the Gamaleya Institute’s Sputnik V vaccine. Like the Sputnik vaccine, EpiVacCorona received approval before a Phase 3 trial to demonstrate that it was safe and effective. That trial is expected to start later this year.
Updated Oct. 14
PHASE 1 PHASE 2 COMBINED PHASES
Sanofi logoGSK logo
In addition to their mRNA vaccine, Sanofi developed a Covid-19 vaccine based on viral proteins. They produced the proteins with engineered viruses that grow inside insect cells. GSK supplemented these proteins with adjuvants that stimulate the immune system. The vaccine is based on the same design Sanofi used to create Flublok, an approved vaccine for influenza. The companies launched a Phase 1/2 clinical trial in September. They plan to start a Phase 3 trial in December and hope to know if the vaccine is safe and effective by the middle of 2021.
Starting before their clinical trials began, Sanofi negotiated several major deals to supply the vaccine, including a $2.1 billion agreement with the United States to provide 100 million doses. On Sept. 18 they closed another deal with the European Union for 300 million doses for an unspecified amount, and later reached an agreement with Canada for up to 72 million doses. In addition, Sanofi agreed to provide 200 million doses to COVAX, an international collaboration to deliver the vaccine equitably across the world. They have plans to make up to one billion doses in 2021.
Updated Oct. 28
PHASE 1 PHASE 2 COMBINED PHASES
spybiotech logo
SpyBiotech, a company spun off from the University of Oxford, announced in September that the first volunteers in an Australian Phase 1/2 trial were receiving their Covid-19 vaccine. The researchers created the vaccine from a mixture of proteins. Some of the proteins, from hepatitis B viruses, assemble themselves into hollow shells. The researchers decorated these shells with part of the coronavirus spike protein. The Serum Institute of India, which licensed the technology from SpyBiotech, is running the trials.
Updated Sept. 24
PHASE 2
West China Hospital of Sichuan University logo
In July, researchers at West China Hospital of Sichuan University published a study in Nature describing a vaccine made from the RBD region of the spike protein that could protect mice and monkeys from the coronavirus. To make the vaccine, researchers encode the RBD region in a gene, which they insert into a virus. They then infect insect cells with the virus, causing them to make the molecule in huge amounts. On Aug. 24, they launched a Phase 1 trial, and on Nov. 16 they moved to Phase 2.
Updated Nov. 20
PHASE 1 PHASE 2 COMBINED PHASES
Baylor College of Medicine logoTexas Children’s Hospital Center for Vaccine Development logo
Biological E logoDynavax logo
After the SARS epidemic in 2002, Baylor College of Medicine researchers began developing a vaccine that could prevent a new outbreak. Despite promising early results, support for the research disappeared. Because the coronaviruses that cause SARS and Covid-19 are very similar, the researchers revived the project in partnership with the Texas Children’s Hospital. The researchers have found that the Covid-19 vaccine produces antibodies in mice. The Indian company Biological E licensed it in August and launched a Phase 1/2 trial in November, combining the viral proteins with an adjuvant made by Dynavax. If trials confirm that the vaccine works, they hope to potentially make a billion doses a year.
Updated Nov. 16
PHASE 1
Clover Biopharmaceuticals logoGSK logoDynavax logo
Clover Biopharmaceuticals has developed a vaccine containing the spike protein from coronaviruses. To further stimulate the immune system, the company is testing so-called adjuvants made by British drugmaker GSK and the American company Dynavax. Investments from CEPI will support the development of manufacturing that could lead to the production of a billion doses a year. Clover’s formula looks to be especially durable; the vaccine can sit out at room temperature for a month and remain viable.
Clover launched a Phase 1 trial in June, and in December they announced that the vaccine triggered a high level of antibodies. The company is following up on the promising results by launching a Phase 2 / 3 trial with the GSK adjuvant by the end of 2020.
Updated Dec. 5
PHASE 1
University of Queensland logoCSL logo
A vaccine from Australia’s University of Queensland delivers viral proteins altered to draw a stronger immune response. Experiments on hamsters showed that the vaccine protected them from the coronavirus. The university launched Phase 1 trials in July, combining the proteins with an adjuvant made by CSL. If the results are positive, CSL will advance late stage clinical trials by the end of 2020. In September the vaccine makers reached an agreement with the Australian government to deliver 51 million doses if the trials deliver positive results. They expected their first supply of the vaccines to be ready in mid-2021.
Updated Sept. 8
PHASE 1
Vaxine logo
The Australian company Vaxine developed a vaccine that combines viral proteins with an adjuvant that stimulates the immune system. A Phase 1 trial began over the summer, and Phase 2 trials are expected to commence by the end of the year.
Updated Sept. 29
PHASE 1
Kentucky BioProcessing logo
A second plant-based vaccine is in development at Kentucky BioProcessing, an American subsidiary of British American Tobacco, the maker of Lucky Strike and other cigarettes. Like Medicago, Kentucky BioProcessing engineers a wild relative of tobacco called Nicotiana benthamiana to make viral proteins. The company previously used this technique to make a drug called Zmapp for Ebola. After preclinical testing in the spring, they registered a Phase 1 trial for their coronavirus vaccine in July. The trial is scheduled to start in December.
Updated Dec. 2
PHASE 1
Medigen logoDynavax logo
Taiwan-based vaccine maker Medigen is making a vaccine made of a combination of spike proteins and an adjuvant from Dynavax. After a series of promising experiments on animals, they began injecting volunteers for a Phase 1 trial in early October.
Updated Oct. 13
PHASE 1
AdImmune logo
Taiwan-based vaccine manufacturer Adimmune got permission to launch a Phase 1 trial on Aug. 20. The vaccine contains the RBD section of the virus’s spike protein.
Updated Aug. 20
PHASE 1
COVAXX logo
New York-based COVAXX, a subsidiary of United Biomedical, has created a vaccine containing parts of several viral proteins. On Sept. 11 they registered a Phase 1 trial in Taiwan. They have reached an agreement with authorities in Brazil to run their Phase 2/3 trial there. On Nov. 25, Covaxx announced agreements with countries including Brazil, Ecuador, and Peru to deliver more than 140 million doses for $2.8 billion.
Updated Nov. 25
PHASE 1
University of Tu¨bingen logo
In the spring, researchers at the University of Tu¨bingen in Germany created a vaccine made of eight parts of two viral proteins, along with an immune-stimulating adjuvant. In September they launched a Phase 1 trial.
Updated Sept. 15
PHASE 1
Finlay Vaccine Institute logo
In October, Cuba’s Finlay Vaccine Institute launched clinical trials on their second experimental vaccine for the coronavirus. Known as Sovereign 2, it contains the RBD part of the coronavirus spike protein. The RBD fragment is fused to a standard tetanus vaccine, which makes it stable. It also uses aluminum hydroxide.
Updated Oct. 28
PHASE 1
Centro de Ingeniería Genética y Biotecnología de Cuba logo
The Center for Genetic Engineering and Biotechnology of Cuba announced on Nov. 26 that it was beginning a Phase 1 trial of a vaccine delivered as a nasal spray. Known as Mambisa, the vaccine contains a piece of the coronavirus spike protein called the receptor-binding domain, along with a protein from the hepatitis B virus that stimulates the immune system. The name refers to women who fought in Cuba’s nineteenth-century wars of independence.
Updated Nov. 30
PHASE 1
Centro de Ingeniería Genética y Biotecnología de Cuba logo
In addition to their nasal spray vaccine, the Center for Genetic Engineering and Biotechnology of Cuba also launched a separate trial at the end of November on a vaccine injected into the muscle. It contains a piece of the coronavirus spike protein called the receptor-binding domain. The vaccine is called Abadala, named after a poem by the nineteenth-century poet José Marti.
Updated Nov. 30
PHASE 1
SK Bioscience logo
SK Bioscience, a South Korean vaccine maker, designed a Covid-19 vaccine based on pieces of the spike protein of the coronavirus. In August they found that the vaccine triggers a strong production of antibodies in monkeys. They launched a Phase 1 trial at the end of November.
Updated Dec. 2
PHASE 1 ?
North Korea logo
On July 18, North Korea’s State Commission of Science and Technology announced on their web site that they had started clinical trials on a vaccine based on part of the coronavirus spike protein. It’s hard to independently evaluate the claim from the isolated dictatorship. The commission claimed to have tested the vaccine on animals, but provided no data. Four months after their announcement, South Korean lawmakers said they had foiled an attempt by North Korea to hack South Korean companies developing coronavirus vaccines. So far, North Korea has not released any further information about the trials they supposedly are running.
Updated Dec. 2
PRECLINICAL
University of Pittsburgh logo
A vaccine in development by the University of Pittsburgh, called PittCoVacc, is a skin patch tipped with 400 tiny needles made of sugar. When placed on the skin, the needles dissolve and deliver virus proteins into the body. Its creators are planning to start clinical trials in late 2020.
Updated Aug. 27
PRECLINICAL
Other protein-based vaccines in active preclinical development include vaccines from: Adaptive Phage Therapeutics; AdaptVac and Bavarian Nordic; Applied Biotechnology Institute; Artes Biotech; Axon Neuroscience; BiOMVis and University of Trento; City College of New York and TechnoVax; EpiVax; GeoVax; Heat Biologics; IBio and CC-Pharming; Icosavax and University of Washington; ImmunoPrecise Antibodies; IMV; Instituto Butantan; Intravacc; IrsiCaixa; Izmir Biomedicine and Genome Center; National Autonomous University of Mexico; Navarrabiomed; NidoVax; OncoGen; Oragenics; OSE Immunotherapeutics; Osivax; PDS Biotechnology; Pontifical Catholic University of Chile; Saiba; SK Bioscience; University of Alberta; University of Amsterdam; University of Georgia and EpiVax; University of Saskatchewan and VIDO-InterVac; University of Virginia; UNSAM-CONICET; Vaxform; Vaxil-Bio; VBI Vaccines; Verndari; VIDO-InterVac; Voltron Therapeutics; Walter Reed Army Institute of Research; Wyss Institute and Harvard University; Yisheng Biopharma.
Updated Sept. 25
Source: https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html
Bloomberg.com – Global Plant-based Biologics Market to surpass US$ 24.9 million by 2027, Says Coherent Market Insights (CMI)
8. Dezember 2020
https://www.bloomberg.com/press-releases/2020-12-08/global-plant-based-biologics-market-to-surpass-us-24-9-million-by-2027-says-coherent-market-insights-cmi
... and some of them are not so dissimilar to us
https://www.npr.org/sections/health-shots/2020/10/15/923210562/tobacco-plants-contribute-key-ingredient-for-covid-19-vaccine?t=1607526129387
iBio is part of the Manhattan Project for BioDefense ...
iBio mentioned at 0:29 - Texas hub for coronavirus research
The Advantages of Implementing Plant-Based Vaccines
Simply saying -That will never happen - is also purely speculative ... and not very constructive.
iBio – For Humanity
As for the search for an effective vaccine against Covid-19, the last sentence is far, far from being spoken. It is therefore secondary in which sentence and with whom iBio is mentioned, but it is very important that it is mentioned and that it is visible that iBio is involved in several vaccine developments. And I also don't see why iBio should now "have no right" to be named together with larger pharmaceutical companies. Nobody knows what the future brings.
This is one of the most encouraging and empowering news I have read in the last few days - any investor who reads this news carefully should know what it can mean for IBIO.
iBio (IBIO) Stock: Don’t Give Up On This One Yet!
https://alphastocknews.com/ibio-ibio-stock-dont-give-up-on-this-one-yet/4059/
interesting post - coincidence that the IBIO vaccine is called IBIO-201?
Why did Bill Gates also fund IDRI??? Why does IDRI and IBIO have a partnership together??? Why did Bill Gates host “EVENT 201” and now IBIO has a vaccine candidate called IBIO-201???
iBio – Built for Pandemics - The Time is Now!!!
https://www.youtube.com/watch?v=S4Y6t-Ue1MQ
iBio – Built for Pandemics - The Time is Now!!!
Drug-Drug Interaction Assessment for Therapeutic Proteins; Draft Guidance for Industry; Availability
https://beta.regulations.gov/document/FDA-2020-D-1480-0004
FDA-2020-D-1480 Includes Therapeutic Proteins in IBIO-CBFO3
iBio Introduces FastGlycaneering Development Service™ to Power Recombinant Protein Production